

Please amend the application as follows:

In the Claims

Please amend Claims 1, 2, 9, 11, 17, 18, 22, 23 and 25 as follows:

alt  
B  
R  
(Amended) A recombinant vector for introducing DNA into an eucaryotic cell, the vector comprising, in operable linkage,

- a) [the] retroviral vector DNA [of] or [corresponding to] at least a portion of [a] the retroviral vector[, which portion is capable of infecting and directing the expression of a coding sequence in target cells] DNA comprising elements necessary for infection and direction of expression in target cells; and
- b) one or more coding sequences wherein at least one sequence encodes for a naturally occurring therapeutic antimicrobial peptide or a biologically active derivative thereof

[for the treatment of at least one disease selected from the group consisting of: mammalian tumors, viral infections, bacterial infections and fungal infections].

2. (Amended) The recombinant vector according to Claim 1 comprising in operable linkage,

- a) a 5' long terminal repeat region comprising the structure U3-R-U5;
- b) one or more of said coding sequences wherein at least one sequence encodes for a naturally occurring therapeutic antimicrobial peptide or a biologically active derivative thereof; and
- c) a 3' long terminal repeat region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region to undergo promoter conversion

[for the treatment of at least one disease selected from the group consisting of: mammalian tumors, viral infections, bacterial infections and fungal infections].

alt  
P2  
a2  
(Amended) A recombinant retroviral vector system comprising:

- a) a recombinant vector for introducing DNA into an eucaryotic cell, the vector comprising, in operable linkage,

- A<sup>2</sup>
- i) [the] retroviral vector DNA [of] or [corresponding to] at least a portion of [a] the retroviral vector[, which is capable of infecting and directing the expression of a coding sequence in target cells] DNA comprising elements necessary for infection and direction of expression in target cells; and
  - ii) one or more coding sequences wherein at least one sequence encodes for at least one naturally occurring therapeutic antimicrobial peptide or a biologically active derivative thereof; and
- b) a packaging cell line harboring at least one retroviral construct coding for proteins required for said retroviral vector to be packaged,  
[for the treatment of at least one disease, selected from mammalian tumors, viral infections, bacterial infections and fungal infections].
- 

- A<sup>3</sup>
11. (Amended) A retroviral particle produced by the recombinant retroviral vector system according to Claim 9 after transfecting [a] the packaging cell line [of a] with the retroviral vector [system according to Claim 10 with the retroviral vector according to Claim 10].
- 

- A<sup>4</sup>
17. (Amended) [Use of a recombinant vector according to Claim 1 for producing a pharmaceutical composition for gene therapy of] A method of treating an individual having at least one disease selected from the group consisting of: tumors, viral infections, bacterial infections and fungal infections, comprising administering the recombinant vector of Claim 1 to the individual.

18. (Amended) [Use of a recombinant retroviral vector system according to Claim 9 for producing a pharmaceutical composition for gene therapy of] A method of treating an individual having at least one disease selected from the group consisting of: tumors, viral infections, bacterial infections and fungal infections, comprising administering the recombinant vector of Claim 9 to the individual.
- 

- A<sup>5</sup>
22. (Amended) [A] An isolated host cell infected with a virion according to Claim 11.

- Sub B<sup>5</sup>
23. (Amended) ~~A method for the treatment of a disease selected from the group consisting of:~~  
a genetic defect, cancer and viral infections, comprising administering to a subject in

Sub B5  
need thereof a therapeutically effective amount of a recombinant retroviral particle produced by transfecting a packaging cell line harboring at least one retroviral or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged, with a recombinant retroviral vector comprising, in operable linkage,

- a) [a] retroviral vector DNA [of] or [corresponding to] at least a portion of [a] the retroviral vector[, which is capable of infecting and directing the expression of a coding sequence in target cells] DNA comprising elements necessary for infection and direction of expression in target cells; and
- b) one or more coding sequences wherein at least one sequence encodes for a naturally occurring therapeutic antimicrobial peptide or a biologically active derivative thereof.

- Ab 25. (Amended) The method according to Claim 23 for the treatment of human immunodeficiency virus infections comprising administering to a subject in need thereof a therapeutically effective amount of said recombinant retroviral particle wherein the coding sequence of said retroviral vector encodes for the amino acid sequence of cecropin or biologically active derivatives thereof.

Please add the following claim:

- A7 ---26. A non-human host cell infected with a virion according to Claim 11.---

#### REMARKS

##### Priority

The Examiner notes that Applicants have not filed a certified copy of PCT/EP96/01001 and DK 0243/95.

Applicants are filing concurrently herewith certified copies of PCT/EP96/01001 and DK 0243/95.